News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
In First Swiss IPO This Year, Arpida Brings In CHF97.2M
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pricing its initial public offering at CHF18 per share - the bottom of its expected range of CHF18 to CHF22 - Arpida AG realized gross proceeds of CHF97.2 million (US$80.9 million) from its debut on the Swiss Stock Exchange May 4.
Twitter
LinkedIn
Facebook
Email
Print
Europe
MORE ON THIS TOPIC
Opinion
US Uncertainty Creates Clinical Trial Leadership Opportunity for Europe
June 16, 2025
·
6 min read
·
Craig Koch
Layoffs
The 5 Largest Biopharma Layoffs of Q1 2025: Updated
May 13, 2025
·
5 min read
·
Angela Gabriel
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
April 16, 2025
·
2 min read
·
Tristan Manalac
Duchenne muscular dystrophy
Committee Recommends EU Trials of Sarepta’s Elevidys Continue, Day After Holds
April 4, 2025
·
2 min read
·
Dan Samorodnitsky